News & Updates

Show Multimedia Only

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Treatment with the novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist ecnoglutide for weight management is safe and results in substantial and sustained weight loss in adults with obesity or overweight but without diabetes, according to a phase III study.

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

29 Jun 2025

In adolescents with homozygous familial hypercholesterolemia (HoFH), treatment with inclisiran appears to be safe and efficacious for reducing low-density lipoprotein cholesterol (LDL-C) levels, according to the results of the first part of the phase III ORION-13* trial.

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

29 Jun 2025

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025 by

The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025

Semaglutide superior to empagliflozin in lowering mortality, CV risks in T2D patients

26 Jun 2025

Treatment with semaglutide may offer some advantage over empagliflozin, with a recent study showing a much lower risk of death and cardiovascular (CV) events among patients with type 2 diabetes (T2D) who received semaglutide.

Semaglutide superior to empagliflozin in lowering mortality, CV risks in T2D patients

26 Jun 2025

Obesity in polytrauma patients appears protective vs death

24 Jun 2025

Polytrauma patients with obesity appear to have a lower risk of death and shorter length of hospital stays, suggests a study.

Obesity in polytrauma patients appears protective vs death

24 Jun 2025

The link between microbes and the gut is being brought to light with the power of AI.

24 Jun 2025 by

Former Dean of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK), Choh-Ming Li Professor of Medicine and Therapeutics, codirector of Microbiota I-Center (MagIC), Gastroenterologist

The link between microbes and the gut is being brought to light with the power of AI.

24 Jun 2025

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

24 Jun 2025 by

A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

24 Jun 2025

Metabolic burden ups risk of death in CHB patients with SLD

23 Jun 2025

Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.

Metabolic burden ups risk of death in CHB patients with SLD

23 Jun 2025

Chronic medical, psychiatric comorbidities common in paediatric hidradenitis suppurativa

21 Jun 2025

Children with hidradenitis suppurativa (HS) are prone to a number of metabolic, endocrinologic, dermatologic, psychiatric, and genetic comorbidities, including obesity, anxiety, and acne vulgaris, according to the findings of a systematic review and meta-analysis.

Chronic medical, psychiatric comorbidities common in paediatric hidradenitis suppurativa

21 Jun 2025

Analogue bests human insulin in T2D patients with kidney failure

20 Jun 2025 by

Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.

Analogue bests human insulin in T2D patients with kidney failure

20 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

Inclisiran confers LDL–C-lowering benefit in adolescents with HoFH

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Semaglutide superior to empagliflozin in lowering mortality, CV risks in T2D patients

Semaglutide superior to empagliflozin in lowering mortality, CV risks in T2D patients

Obesity in polytrauma patients appears protective vs death

Obesity in polytrauma patients appears protective vs death

The link between microbes and the gut is being brought to light with the power of AI.

The link between microbes and the gut is being brought to light with the power of AI.

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

Metabolic burden ups risk of death in CHB patients with SLD

Metabolic burden ups risk of death in CHB patients with SLD

Chronic medical, psychiatric comorbidities common in paediatric hidradenitis suppurativa

Chronic medical, psychiatric comorbidities common in paediatric hidradenitis suppurativa

Analogue bests human insulin in T2D patients with kidney failure

Analogue bests human insulin in T2D patients with kidney failure